Tacalyx Extends Seed Round to over €14 M to Advance Development of its Cancer Therapeutics

Tacalyx GmbH, a Berlin-based biotech company, has extended its seed financing to over €14 million. This round was led by new investor Thuja Capital, with Evan Castiglia, Partner at Thuja Capital, joining the Board of Directors. Existing investors include Boehringer Ingelheim Venture Fund, Kurma Partners, High-Tech Gründerfonds, coparion, IdInvest/Eurazeo, Creathor Ventures, and the Max-Planck-Society.

Tacalyx focuses on developing antibody-based therapeutics targeting Tumor Associated Carbohydrate Antigens (TACAs). This technology aims to target cancer cells specifically, offering various treatment modalities like antibody-drug conjugates and T cell engagers. The new funds will support the development of two novel antibodies to the late preclinical stage and advance several earlier-stage programs.

Dr. Peter Sondermann, CEO of Tacalyx, expressed optimism about the extended seed funding, highlighting the potential of their technology to create new cancer treatment options. The company plans to develop pipeline candidates further and explore partnerships to enhance their research efforts.